CompletedNCT01666470Updated Feb 18, 2019

Quality of Life of Patients With a History of Drug Allergy in Thailand

An observational study in Quality of Life, sponsored by Chulalongkorn University. Completed at 2 sites in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-18.

Sponsored by Chulalongkorn University · Observational

Study type: Observational
Model: Cohort
Time perspective: Cross-sectional
Enrollment: 306
Ages: 18 Years and older
Sex: All

Study summary

Quality of life of patients with a history of drug allergy in Thailand will be studied.

Read the detailed description

Thai patients with a history of drug allergy will be evaluated for their quality of life based on drug hypersensitivity quality of life questionnaire (DrHy-Q; Thai version) and The World Health Organization Quality of Life instrument (WHOQOL-BREF-THAI)

Conditions studied

Quality of Life

Browse trials for

Drug Hypersensitivity 66

Keywords

Quality of life

In context

Drug Hypersensitivity

66 studies on the registry are indexed under Drug Hypersensitivity; 20 are open to participants now.

This study's enrollment of 306 is above the median of 200 across 28 observational studies indexed under Drug Hypersensitivity.

Browse Drug Hypersensitivity studies →

Lead sponsor

Chulalongkorn University is the lead sponsor of 312 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Thai patients with a history of drug allergy

Inclusion criteria

Have a history of drug allergy
At least 18 years of age

Exclusion criteria

Exclusion Criteria:

Not be able to understand Thai language

Study design

Observational model: Cohort
Time perspective: Cross-sectional
Enrollment: 306 participants (actual)

Groups and cohorts

Drug allergy patients
Patients with a history of drug allergy in Thailand
Other: Questionnaires

Interventions

OtherQuestionnaires
DrHy-Q (Thai version) and WHOQOL-BREF-THAI will be asked

What researchers measure

Primary outcomes

The quality of life of Thai patients with a history of drug allergy evaluating by DrHy-Q (Thai version)
Time frame: 1 year

Secondary outcomes

The correlation between DrHy-Q (Thai version) and WHOQOL-BREF-THAI
Pearson correlation coefficient between scores from DrHy-Q (Thai version) and WHOQOL-BREF-THAI in patients with a history of drug allergy will be analyzed.
Time frame: 1 year

Study locations

2 sites

Faculty of Medicine, Chulalongkorn University
Bangkok, 10330, Thailand
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Bangkok, Thailand

References and documents

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Feb 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT01666470
Lead sponsor: Chulalongkorn University
Collaborators: Mahidol University
Responsible party: Jettanong Klaewsongkram (Head of Division of Allergy and Clinical Immunology, Department of Medicine, Chulalongkorn University) — Principal investigator
First posted: Aug 16, 2012
Start date: Aug 2012
Primary completion: Aug 2017
Completion: Oct 2017
Last update: Feb 18, 2019

Study contacts

Jettanong Klaewsongkram, MD

principal investigator · Chulalongkorn University

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Drug Hypersensitivity→

Other studies from this sponsor

Chulalongkorn University

Start the discussion